Matches in Nanopublications for { ?s ?p "The c-MET serves as an attractive therapeutic target in SCLC, as shown through small interfering RNA (siRNA) and selective prototype c-MET inhibitor SU11274, inhibiting the phosphorylation of c-MET itself and its downstream molecules such as AKT, S6 kinase, and ERK1/2. The HGF-stimulated phosphorylation of the following downstream phosphokinases was inhibited by SU11274: p-ERK1 [T202/Y204], p-ERK1/2 [T185/Y187], p-MEK1/2 [S221/S225], p38a p-MAP kinase [T180/Y182], p-AKT1 [S473], p-RB [S672], p-adducin-g [S662], and p-CREB [S133]). SU11274 was also effective in abrogating the inhibitory effect of HGF on the specific phosphorylation of p-PKCa [S657], p-PKCa/b [T368], and p-CDK1 [T14/Y15] (Figure 6B)." ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- _4 value "The c-MET serves as an attractive therapeutic target in SCLC, as shown through small interfering RNA (siRNA) and selective prototype c-MET inhibitor SU11274, inhibiting the phosphorylation of c-MET itself and its downstream molecules such as AKT, S6 kinase, and ERK1/2. The HGF-stimulated phosphorylation of the following downstream phosphokinases was inhibited by SU11274: p-ERK1 [T202/Y204], p-ERK1/2 [T185/Y187], p-MEK1/2 [S221/S225], p38a p-MAP kinase [T180/Y182], p-AKT1 [S473], p-RB [S672], p-adducin-g [S662], and p-CREB [S133]). SU11274 was also effective in abrogating the inhibitory effect of HGF on the specific phosphorylation of p-PKCa [S657], p-PKCa/b [T368], and p-CDK1 [T14/Y15] (Figure 6B)." provenance.